What to do after resistance to sunitinib

Sunitinib (Sunitinib) is a VEGFR tyrosine kinase inhibitor that has been approved as a first-line treatment for patients with advanced renal cell carcinoma (RCC) for more than a decade. However, patients treated with sunitinib gradually develop resistance to the drug. Immune checkpoint inhibitors (ICIs) have been approved as second-line treatments for patients with advanced renal cell carcinoma who are resistant to anti-angiogenic therapy. However, how the development of resistance to anti-angiogenesis inhibitors affects the efficacy of ICIs remains unknown. Everolimus is suitable for the treatment of patients with advanced renal cell carcinoma after failure of sunitinib treatment. Axitinib also provides physicians and patients with advanced renal cell carcinoma a new treatment option after sunitinib treatment or cytokine therapy.